< All Topics

ICH Guidelines for Clinical Safety

ICH Guidelines for Clinical Safety

The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) has developed a set of guidelines for the clinical evaluation of pharmaceuticals, including guidelines for clinical safety. These guidelines are designed to ensure that the safety of patients is given the highest priority in the development and evaluation of new drugs.

The following are some of the key ICH guidelines for clinical safety:

  1. ICH E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting: This guideline provides definitions for key terms related to clinical safety data and outlines the standards for expedited reporting of adverse events.
  2. ICH E2C: Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs: This guideline outlines the requirements for periodic safety update reports (PSURs) for marketed drugs. PSURs are comprehensive reports that provide a summary of the safety data for a drug over a defined period of time.
  3. ICH E4: Dose-Response Information to Support Drug Registration: This guideline provides recommendations on the use of dose-response information to support drug registration. It includes guidance on designing dose-response studies and interpreting the results.
  4. ICH E6: Good Clinical Practice: This guideline provides a framework for the design, conduct, monitoring, auditing, recording, analysis, and reporting of clinical trials. It includes guidance on the collection and reporting of safety data.
  5. ICH E8: General Considerations for Clinical Trials: This guideline provides general principles for the design, conduct, and reporting of clinical trials. It includes guidance on the assessment of safety and the use of safety data to inform clinical trial design.

These guidelines are intended to promote the safety of patients in clinical trials and in the use of approved drugs. It is important for researchers and pharmaceutical companies to adhere to these guidelines to ensure that their products are safe and effective.

You may be interested in the programs below: